Abstract :Abstract
Meglitinides promote pancreas insulin secretion, and have a short half-life in plasma; they are often termed "short-acting-type insulin secretagogues”. They primarily control postprandial blood glucose. On the basis of these characteristics, various controlled-release preparations containing meglitinides are currently being developed to achieve precise and/or timely control of blood glucose, or to reduce the dosing frequency, or to enable a more convenient administration route. If approved, it is hoped that they will increase quality of life for diabetes patients.